PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 9934640

When one is two.

S Taggart·D Parry
View original source ↗Export metadata ↓

Abstract

This article is about Karen, who was 20 weeks pregnant when she was involved in a gas explosion. The explosion caused a 35% body surface area deep partial-thickness burn to her legs and arms. This article focuses on the most important concerns and fears Karen expressed while she was in our care. Her statements triggered various clinical memories from several nurses in the burn unit, and thus the stories unfold. These stories reflect nursing practice through the psychological care, clinical signs, and pathophysiology of our patient. The spoken stories, coupled with the reflective stories, provide a total picture of the multidimensional care nurses provide for their patients.

Explore related subjects

AnalgesicsAttitude of Health PersonnelBurn UnitsBurnsFemaleHumansInfant, NewbornMalePainPregnancyPregnancy ComplicationsCase ReportsJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S Taggart, D Parry. When one is two.. https://doi.org/10.1097/00004630-199901001-00017

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2000

Use of detomidine hydrochloride as an adjunct for studying first-stage Gasterophilus intestinalis (Diptera: Gasterophilidae) in the tongue of the horse.

A synthetic alpha-2 adrenergic agonist, detomidine hydrochloride, was used in the study of in vivo activity of Gasterophilus intestinalis (Diptera: Gasterophilidae) during migration in the tongue of the horse. Use of the drug allowed the investigator to manipulate the tongue and closely observe the movement patterns and tissue disturbance caused by burrowing first-stage larvae. Detomidine hydrochloride should be utilized in studies of drug efficacy and larval biology, whenever possible, to avoid the need to sacrifice the horse.

Analgesics↗
PubMed2000

[Pharmacotherapy of patients with (early) rheumatoid arthritis].

As soon as the diagnosis 'early rheumatoid arthritis (RA)' is made, a disease-modifying antirheumatic drug (DMARD) should be prescribed without delay. Methotrexate in dosages up to 30 mg once weekly is being used more frequently than in the past, also in early RA. Combination therapy with DMARDs is indicated in case of insufficient effect of a single DMARD. Combinations with methotrexate appear to be especially effective, like methotrexate and cyclosporin. A novel effective DMARD is leflunomide. In the near future promising biologicals will probably be applied in clinical daily practice, presumably in combination with conventional DMARDs. New non-steroidal anti-inflammatory drugs (NSAIDs) have been developed that are probably safer than conventional NSAIDs. If the recent finding that glucocorticoids are able to inhibit joint damage in (early) RA will be confirmed, prednisone might be used more often in (early) RA. Bone marrow transplantation in RA is still experimental.

Analgesics↗